Details of the Drug
General Information of Drug (ID: DMNXQ7Z)
| Drug Name |
1,2,3,4-Tetrahydro-naphthalen-1-ylamine
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
1,2,3,4-Tetrahydro-1-naphthylamine; 2217-40-5; 1,2,3,4-tetrahydronaphthalen-1-amine; 1-Aminotetralin; Aminotetralin; 1-Amino-1,2,3,4-tetrahydro-naphthalene; Aminotetralin [Czech]; 1,2,3,4-tetrahydronaphthylamine; JRZGPXSSNPTNMA-UHFFFAOYSA-N; EINECS 220-973-7; beta-1,2,3,4-Tetrahydronaphthylamine; Naphthalenamine, 1,2,3,4-tetrahydro-; BRN 1102357; 1-Amino-1,2,3,4-tetrahydronaphthalene; 1,2,3,4-tetrahydronaphthalen-1-ylamine; 1-Naphthalenamine, 1,2,3,4-tetrahydro-
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 147.22 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.6 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


